119 related articles for article (PubMed ID: 10537347)
1. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression.
Cheng L; Pisansky TM; Sebo TJ; Leibovich BC; Ramnani DM; Weaver AL; Scherer BG; Blute ML; Zincke H; Bostwick DG
Clin Cancer Res; 1999 Oct; 5(10):2820-3. PubMed ID: 10537347
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
3. Extranodal extension in lymph node-positive prostate cancer.
Cheng L; Pisansky TM; Ramnani DM; Leibovich BC; Cheville JC; Slezak J; Bergstralh EJ; Zincke H; Bostwick DG
Mod Pathol; 2000 Feb; 13(2):113-8. PubMed ID: 10697266
[TBL] [Abstract][Full Text] [Related]
4. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?
Cheng L; Leibovich BC; Bergstralh EJ; Scherer BG; Pacelli A; Ramnani DM; Zincke H; Bostwick DG
Cancer; 1999 Jun; 85(11):2455-9. PubMed ID: 10357418
[TBL] [Abstract][Full Text] [Related]
5. Dedifferentiation in the metastatic progression of prostate carcinoma.
Cheng L; Slezak J; Bergstralh EJ; Cheville JC; Sweat S; Zincke H; Bostwick DG
Cancer; 1999 Aug; 86(4):657-63. PubMed ID: 10440694
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
8. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases.
Fleischmann A; Schobinger S; Schumacher M; Thalmann GN; Studer UE
Prostate; 2009 Mar; 69(4):352-62. PubMed ID: 19016478
[TBL] [Abstract][Full Text] [Related]
9. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
10. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
Boormans JL; Wildhagen MF; Bangma CH; Verhagen PC; van Leenders GJ
BJU Int; 2008 Dec; 102(11):1589-93. PubMed ID: 18710447
[TBL] [Abstract][Full Text] [Related]
11. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
12. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
13. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
14. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
Bader P; Burkhard FC; Markwalder R; Studer UE
J Urol; 2003 Mar; 169(3):849-54. PubMed ID: 12576797
[TBL] [Abstract][Full Text] [Related]
15. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
16. Cancer volume of lymph node metastasis predicts progression in prostate cancer.
Cheng L; Bergstralh EJ; Cheville JC; Slezak J; Corica FA; Zincke H; Blute ML; Bostwick DG
Am J Surg Pathol; 1998 Dec; 22(12):1491-500. PubMed ID: 9850175
[TBL] [Abstract][Full Text] [Related]
17. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.
Briganti A; Capitanio U; Chun FK; Gallina A; Suardi N; Salonia A; Da Pozzo LF; Colombo R; Di Girolamo V; Bertini R; Guazzoni G; Karakiewicz PI; Montorsi F; Rigatti P
Eur Urol; 2008 Oct; 54(4):794-802. PubMed ID: 18514383
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
[TBL] [Abstract][Full Text] [Related]
19. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
20. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
